Cadrenal Therapeutics
CVKD
20 hedge funds and large institutions have $824K invested in Cadrenal Therapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.27% more ownership
Funds ownership: 5.58% → 5.85% (+0.27%)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
48% less capital invested
Capital invested by funds: $1.57M → $824K (-$751K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$284K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.01K |
| 5 |
Morgan Stanley
New York
|
+$2.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$274K |
| 2 |
LPL Financial
San Diego,
California
|
-$13.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.7K |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
-$2.41K |
| 5 |
CWA
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
|
-$277 |
CVKD Hedge Fund Activity: Q4 2025 in Review
20 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q4 2025, worth a combined $824K — down 48% from $1.57M a quarter earlier.
Fund positioning in CVKD was balanced in Q4 2025: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $284K. The largest seller was Citadel Advisors, exiting entirely with an estimated $274K sold.
- 20 institutional investors held Cadrenal Therapeutics (CVKD) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $824K of Cadrenal Therapeutics stock for Q4 2025, down 48% quarter-over-quarter.
- 3 funds opened new Cadrenal Therapeutics positions in Q4 2025 and 3 closed out, a net change of 0 holders.
- The largest Cadrenal Therapeutics buyer in Q4 2025 was DRW Securities, an estimated $284K added.
- The largest Cadrenal Therapeutics seller in Q4 2025 was Citadel Advisors, an estimated $274K sold.
Based on aggregated 13F filings for Q4 2025.